Clinical Trials Browser

Interventional × cobimetinib × Dermatologic × Clear all

NCT03175432 2026-04-15

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04835805 2026-03-30

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Phase 1 Active not recruiting

Melanoma

NCT07449754 2026-03-04

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

Phase 2 Recruiting

Melanoma

NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Active not recruiting

Melanoma, Skin Neoplasms

NCT04109456 2026-01-15

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Phase 1 Completed

Melanoma

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase 3 Completed

514 enrolled 25 charts 3 FDA

Melanoma

NCT02902029 2025-04-09

ImmunoCobiVem

Phase 2 Completed

Melanoma

NCT04722575 2025-03-13

NEO-TIM

Phase 2 Active not recruiting

Melanoma

NCT03101254 2024-07-17

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Phase 1/2 Completed

5 enrolled 10 charts

Melanoma

NCT04190628 2024-05-21

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Phase 1 Terminated

CNSDermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Ovarian Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03625141 2024-04-11

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Phase 2 Completed

80 enrolled 20 charts

Melanoma

NCT05756556 2024-02-01

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Phase 2 Suspended

Melanoma

NCT03430947 2023-09-14

RadioCoBRIM

Phase 2 Terminated

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Phase 1/2 Completed

113 enrolled 22 charts

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT02414750 2022-11-30

REPOSIT

Phase 2 Terminated

Melanoma

NCT02036086 2022-10-27

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Phase 2 Unknown

Melanoma

NCT01689519 2022-05-02

coBRIM

Phase 3 Completed

495 enrolled 15 charts

Melanoma

NCT01959633 2022-02-24

VEMUPLINT

Phase 1/2 Completed

Melanoma

NCT02818023 2022-01-03

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

Phase 1 Terminated

Melanoma

NCT03178851 2021-11-19

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

Phase 1 Completed

155 enrolled 22 charts

Melanoma

NCT03224208 2021-04-26

VECODUE

Phase 2 Terminated

Melanoma

NCT02303951 2021-02-03

NEO-VC

Phase 2 Terminated

Melanoma

NCT01656642 2020-07-21

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Phase 1 Completed

Melanoma

NCT02583516 2020-02-17

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT02537600 2020-01-27

CONVERCE

Phase 2 Completed

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02768207 2019-08-28

A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Phase 2 Completed

Melanoma

NCT01271803 2019-07-29

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Phase 1 Completed

131 enrolled 32 charts

Melanoma

NCT01813214 2019-02-26

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

Phase 2 Terminated

5 enrolled 7 charts

Melanoma

NCT02457793 2018-11-20

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

24 enrolled 27 charts

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT01876641 2018-09-19

ML28604

Phase 1 Terminated

Melanoma

NCT01495988 2017-10-24

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Phase 2 Terminated

10 enrolled 10 charts

Melanoma

NCT02427893 2016-11-15

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Phase 3 Withdrawn

Melanoma